Evidence map›Paper›PMID 35026004›Full record

ArticleBlood2022

Granulocyte microvesicles with a high plasmin generation capacity promote clot lysis and improve outcome in septic shock.

Sylvie Cointe, Loris Vallier, Pierre Esnault, Mathilde Dacos, Amandine Bonifay, Nicolas Macagno, Karim Harti Souab, Corinne Chareyre, Coralie Judicone, Diane Frankel and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Role of COX6C and NDUFB3 in septic shock and stroke.Open medicine (Warsaw, Poland) · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Plasminogen System in the Pathophysiology of Sepsis: Upcoming Biomarkers.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Sylvie CointeAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.ORCID 0000-0001-6539-7879
Loris VallierAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.ORCID 0000-0003-2460-4645
Pierre EsnaultIntensive Care Unit, Sainte Anne Military Hospital, Toulon, France.
Mathilde DacosAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Amandine BonifayAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Nicolas MacagnoDepartment of Pathology and Neuropathology, CHU Timone, APHM, Marseille, France.ORCID 0000-0002-9882-2162
Karim Harti SouabIntensive Care Unit, CHU La Conception, APHM, Marseille, France.
Corinne ChareyreAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Coralie JudiconeR and T Department, BioCytex, Marseille, France.
Diane FrankelDepartment of Cell Biology, Aix-Marseille University, APHM, INSERM, MMG, CHU Timone, APHM, Marseille, France.ORCID 0000-0003-3321-6951
Stéphane RobertAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Sami HraiechIntensive Care Unit, APHM, CHU Nord, CEReSS-Center for Studies and Research on Health Services and Quality of Life EA3279, Aix-Marseille University, Marseille, France; and.
Marie-Christine AlessiAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Philippe PonceletR and T Department, BioCytex, Marseille, France.
Jacques AlbaneseIntensive Care Unit, CHU La Conception, APHM, Marseille, France.
Françoise Dignat-GeorgeAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.
Romaric LacroixAix-Marseille University, C2VN, INSERM 1263, INRA 1260, Marseille, France.ORCID 0000-0002-5756-470X
Inserm · FRHôpital de la Conception · FRAix-Marseille Université · FRHôpital d'Instruction des Armées Sainte-Anne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microvesicles (MVs) have previously been shown to exert profibrinolytic capacity, which is increased in patients with septic shock (SS) with a favorable outcome. We, therefore, hypothesized that the plasmin generation capacity (PGC) could confer to MVs a protective effect supported by their capacity to lyse a thrombus, and we investigated the mechanisms involved. Using an MV-PGC kinetic assay, ELISA, and flow cytometry, we found that granulocyte MVs (Gran-MVs) from SS patients display a heterogeneous PGC profile driven by the uPA (urokinase)/uPAR system. In vitro, these MVs lyse a thrombus according to their MV-PGC levels in a uPA/uPAR-dependent manner, as shown in a fluorescent clot lysis test and a lysis front retraction assay. Fibrinolytic activators conveyed by MVs contribute to approximately 30% of the plasma plasminogenolytic capacity of SS patients. In a murine model of SS, the injection of high PGC Gran-MVs significantly improved mouse survival and reduced the number of thrombi in vital organs. This was associated with a modification of the mouse coagulation and fibrinolysis properties toward a more fibrinolytic profile. Interestingly, mouse survival was not improved when soluble uPA was injected. Finally, using a multiplex array on plasma from SS patients, we found that neutrophil elastase correlates with the effect of high-PGC-capacity plasma and modulates the Gran-MV plasmin generation capacity by cleaving uPA-PAI-1 complexes. In conclusion, we show that the high PGC level displayed by Gran-MVs reduces thrombus formation and improves survival, conferring to Gran-MVs a protective role in a murine model of sepsis.

Indexed as

Shock, SepticThrombosisAnimalsDisease Models, AnimalFibrinolysinFibrinolysisGranulocytesHumansMiceUrokinase-Type Plasminogen ActivatorFibrinolysinUrokinase-Type Plasminogen Activator

Identifiers

PMID35026004
PMCPMC11022829
OpenAlexW4205464325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.